| pubmed-article:16143246 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16143246 | lifeskim:mentions | umls-concept:C0018823 | lld:lifeskim |
| pubmed-article:16143246 | lifeskim:mentions | umls-concept:C1511726 | lld:lifeskim |
| pubmed-article:16143246 | lifeskim:mentions | umls-concept:C0676831 | lld:lifeskim |
| pubmed-article:16143246 | lifeskim:mentions | umls-concept:C0175989 | lld:lifeskim |
| pubmed-article:16143246 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:16143246 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
| pubmed-article:16143246 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:16143246 | pubmed:dateCreated | 2005-9-6 | lld:pubmed |
| pubmed-article:16143246 | pubmed:abstractText | More children are coming to heart transplantation on extracorporeal membrane oxygenation (ECMO), or inotropic support and/or with renal impairment. The use of basiliximab, a chimeric monoclonal antibody against CD25 (interleukin 2 receptor alfa) has not been previously reported in critically ill pediatric heart transplant recipients. Basiliximab has potential advantages in the treatment of patients with renal impairment. | lld:pubmed |
| pubmed-article:16143246 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16143246 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16143246 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16143246 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16143246 | pubmed:issn | 1557-3117 | lld:pubmed |
| pubmed-article:16143246 | pubmed:author | pubmed-author:ElliottMartin... | lld:pubmed |
| pubmed-article:16143246 | pubmed:author | pubmed-author:BurchMichaelM | lld:pubmed |
| pubmed-article:16143246 | pubmed:author | pubmed-author:CaleCatherine... | lld:pubmed |
| pubmed-article:16143246 | pubmed:author | pubmed-author:FordKatrina... | lld:pubmed |
| pubmed-article:16143246 | pubmed:author | pubmed-author:ReesPhilip... | lld:pubmed |
| pubmed-article:16143246 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:16143246 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:16143246 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16143246 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16143246 | pubmed:pagination | 1284-8 | lld:pubmed |
| pubmed-article:16143246 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:meshHeading | pubmed-meshheading:16143246... | lld:pubmed |
| pubmed-article:16143246 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16143246 | pubmed:articleTitle | Initial data on basiliximab in critically ill children undergoing heart transplantation. | lld:pubmed |
| pubmed-article:16143246 | pubmed:affiliation | Pharmacy Department, Great Ormond Street Hospital for Children, London, United Kingdom. fordk2@gosh.nhs.uk | lld:pubmed |
| pubmed-article:16143246 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16143246 | pubmed:publicationType | Clinical Trial | lld:pubmed |
